Woodline Partners’s Kura Oncology KURA Stock Holding History

Woodline Partners’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Hold	145,704	–	–	﹤0.01%	860
2026 Q1	$1.18M	Hold	145,704	–	–	﹤0.01%	863
2025 Q4	$1.51M	Hold	145,704	–	–	0.01%	807
2025 Q3	$1.29M	Hold	145,704	–	–	0.01%	781
2025 Q2	$841K	Hold	145,704	–	–	﹤0.01%	819
2025 Q1	$962K	Sell	145,704 -27,000	-16%	-$210K	0.01%	767
2024 Q4	$1.5M	Buy	172,704 +29,497	+21%	+$424K	0.01%	697
2024 Q3	$2.8M	Hold	143,207	–	–	0.02%	445
2024 Q2	$2.95M	Buy	+143,207	New	+$2.94M	0.03%	387
2023 Q3	–	Sell	-867,062	Closed	-$9.17M	–	681
2023 Q2	$9.17M	Buy	867,062 +377,530	+77%	+$4.47M	0.11%	216
2023 Q1	$5.99M	Buy	+489,532	New	+$6.11M	0.08%	264
2022 Q4	–	Sell	-267,683	Closed	-$3.66M	–	809
2022 Q3	$3.66M	Hold	267,683	–	–	0.05%	351
2022 Q2	$4.91M	Hold	267,683	–	–	0.08%	263
2022 Q1	$4.3M	Hold	267,683	–	–	0.07%	261
2021 Q4	$3.75M	Hold	267,683	–	–	0.05%	323
2021 Q3	$5.01M	Hold	267,683	–	–	0.08%	248
2021 Q2	$5.58M	Buy	+267,683	New	+$6.65M	0.1%	208

Other funds holding KURA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Woodline Partners's KURA Position: Q2 2026 in Review

Woodline Partners held its Kura Oncology (KURA) position steady in Q2 2026 at 145,704 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Woodline Partners first reported a position in KURA in Q2 2021 and has held it in 17 quarters since. The position peaked at $9.17M in Q2 2023. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

Woodline Partners held 145,704 shares of Kura Oncology worth $1.6M as of Q2 2026.
Woodline Partners left its Kura Oncology share count unchanged in Q2 2026.
Kura Oncology made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #860 holding.
Woodline Partners first reported a position in Kura Oncology in Q2 2021 and has held it in 17 quarters since.
Woodline Partners's Kura Oncology position peaked at $9.17M in Q2 2023.
221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.